Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...
Clinical Trial
Applied Molecular Transport Announces Top-line Phase 2 Results from LOMBARD Monotherapy Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis
– Similar clinical remission rates observed in patients receiving AMT-101 monotherapy compared to placebo at week 12 – AMT-101 was...
Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL
The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complicationNEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE)...
Mersana Therapeutics Announces Research Collaboration and Commercial License Agreement with Merck KGaA, Darmstadt, Germany to Develop Novel Immunosynthen Antibody-Drug Conjugates
Collaboration focuses on discovering novel STING-agonist ADCs for up to two targets leveraging Mersana’s proprietary immunostimulatory platform Mersana to receive...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
TORONTO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a...
Ryvu Therapeutics Announces Closing of Equity Offering with Gross Proceeds Over PLN 250 Million
KRAKOW, Poland, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ryvu Therapeutics , a clinical-stage drug discovery and development company focusing on novel...
Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets
- Ceapro is pioneering approach with a natural product as a potential anti-inflammatory - Clinical study to be conducted with the...
Y-mAbs Announces Partnership Regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
NEW YORK, Dec. 21, 2022 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Update on First BioNTainer for African-based mRNA Manufacturing Facility
MAINZ, GERMANY, December 21, 2022 — BioNTech SE (Nasdaq: BNTX, “BioNTech”) reached the next milestone in the establishment of scalable...
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows...
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
– Cohort 4 Dosing Stopped per Clinical Trial Protocol due to Dose-Limiting Toxicities – – Plan to Dose Additional Participants...
Updated Invectys and CTMC announce FDA clearance of IND application for anti-HLA-G CAR-T cell therapy
FDA granted IND clearance for IVS-3001, Invectys’s lead engineered anti-HLA-G CAR-T cell therapy, for the treatment of patients with solid...
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
Phase 3, registrational studies remain on track for first half of 2023 topline data readoutSCOTTSDALE, Ariz., Dec. 20, 2022 (GLOBE...
POINT Biopharma Announces Closing of Agreements with Lantheus Holdings
INDIANAPOLIS, Dec. 20, 2022 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (“POINT”) (NASDAQ: PNT), a company accelerating the discovery, development,...
IGC Announces Updated Life Sciences Presentation
POTOMAC, Md., Dec. 20, 2022 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), today...
Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer
Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec....
Femasys Inc. Announces Commercial Availability of its FemCath Intrauterine Device
-- FemCath™ is the first FDA-cleared intrauterine catheter that allows for selective evaluation of a fallopian tube with contrast -- --...
Altamira Therapeutics Provides Year-End 2022 Business Update
Hamilton, Bermuda, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Altamira Therapeutics Provides Year-End 2022 Business Update Strategic BentrioTM partnering or divestiture...
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
MB-106 clinical trial under Mustang’s IND continues to enroll patients Additional IND filing and published research expected in 2023 across...
Albireo Submits Bylvay® Alagille Syndrome Regulatory Filings to FDA and EMA
- Gold standard Phase 3 ASSERT study supports supplementary filings in the U.S. and EU - ASSERT study demonstrated efficacy...